Clinical Trials Logo

Malignant Mesothelioma clinical trials

View clinical trials related to Malignant Mesothelioma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04173338 Terminated - Clinical trials for Non Small Cell Lung Cancer

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Start date: January 23, 2020
Phase: Phase 1
Study type: Interventional

This study will combine cabozantinib with pemetrexed to treat patients with non-small cell lung cancer, urothelial cancer and advanced malignant mesothelioma. This study will test the safety of both drugs used together and see what effect (good or bad) it has no participants and their cancer.

NCT ID: NCT00898547 Terminated - Clinical trials for Malignant Mesothelioma

Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107

Start date: November 2005
Phase:
Study type: Observational

RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about cancer and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers of angiogenesis and disease in patients with unresectable malignant mesothelioma treated on clinical trial CALGB-30107.

NCT ID: NCT00027508 Terminated - Clinical trials for Malignant Mesothelioma

Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma

Start date: July 2001
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have malignant mesothelioma that cannot be removed by surgery.

NCT ID: NCT00003508 Terminated - Clinical trials for Malignant Mesothelioma

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

Start date: March 8, 1996
Phase: Phase 2
Study type: Interventional

Current therapies for advanced Mesothelioma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of advanced Mesothelioma. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with advanced Mesothelioma.